Research ArticleNovel Imaging Probes
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
Christopher G. England, Emily B. Ehlerding, Reinier Hernandez, Brian T. Rekoske, Stephen A. Graves, Haiyan Sun, Glenn Liu, Douglas G. McNeel, Todd E. Barnhart and Weibo Cai
Journal of Nuclear Medicine January 2017, 58 (1) 162-168; DOI: https://doi.org/10.2967/jnumed.116.177857
Christopher G. England
1Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin
Emily B. Ehlerding
1Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin
Reinier Hernandez
1Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin
Brian T. Rekoske
2Department of Medicine, University of Wisconsin–Madison, Madison, Wisconsin
Stephen A. Graves
1Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin
Haiyan Sun
3Department of Radiology, University of Wisconsin–Madison, Madison, Wisconsin; and
Glenn Liu
2Department of Medicine, University of Wisconsin–Madison, Madison, Wisconsin
4University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Douglas G. McNeel
2Department of Medicine, University of Wisconsin–Madison, Madison, Wisconsin
4University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Todd E. Barnhart
1Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin
Weibo Cai
1Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin
3Department of Radiology, University of Wisconsin–Madison, Madison, Wisconsin; and
4University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 1
January 1, 2017
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
Christopher G. England, Emily B. Ehlerding, Reinier Hernandez, Brian T. Rekoske, Stephen A. Graves, Haiyan Sun, Glenn Liu, Douglas G. McNeel, Todd E. Barnhart, Weibo Cai
Journal of Nuclear Medicine Jan 2017, 58 (1) 162-168; DOI: 10.2967/jnumed.116.177857
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
Christopher G. England, Emily B. Ehlerding, Reinier Hernandez, Brian T. Rekoske, Stephen A. Graves, Haiyan Sun, Glenn Liu, Douglas G. McNeel, Todd E. Barnhart, Weibo Cai
Journal of Nuclear Medicine Jan 2017, 58 (1) 162-168; DOI: 10.2967/jnumed.116.177857
Jump to section
Related Articles
Cited By...
- Imaging of Activated T Cells
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
- Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer
- Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab')2 Fragments of Obinutuzumab in Lymphoma
- Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
- Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy
- 89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
- Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?
- PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
- Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model
- IFN{gamma} PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy
- Theranostics Using Antibodies and Antibody-Related Therapeutics